BACKGROUND: Iron is used as an adjunct therapy to treat anaemia in dialysis patients. However, iron may harbour detrimental effects in being a nutrient for invading pathogens or by modulating immune pathways. Thus, we prospectively studied the effects of iron treatment towards monocyte immune function. METHODS:Twenty-four haemodialysis patients in whom iron therapy was withheld for 2 weeks before study entry were randomly assigned to receive either a single parenteral dose of iron sucrose or saline (control), and the effects on iron status and immune function of patients' monocytes were analysed during follow-up. RESULTS: At baseline, we found an inverse relationship between serum ferritin levels and the inducibility of patients' monocytes for interleukin-6 and tumour necrosis factor-alpha formation following ex vivo immune stimulation. However, 48 h after intravenous iron administration, we observed a transient increase of tumour necrosis factor-alpha and interleukin-6 formation by unstimulated monocytes as compared with control subjects. This could be traced back to increased phosphorylation of nuclear factor kappa-B p65 in monocytes following iron treatment, which was more pronounced when pre-treatment serum ferritin levels were low. In parallel, intravenous iron injection resulted in storage of the metal in circulating monocytes as reflected by an increase of intracellular ferritin levels, and the amount of iron retention was positively associated with circulating concentrations of the iron regulatory peptide hepcidin. CONCLUSIONS: Intravenously administered iron is taken up by monocytes and leads to short-term activation of the nuclear factor kappa-B pathway. However, increased circulating ferritin levels are associated with an impaired immune response of monocytes. In addition, circulating hepcidin concentrations may determine the erythropoietic response to iron injection by modifying iron retention within monocytes.
RCT Entities:
BACKGROUND:Iron is used as an adjunct therapy to treat anaemia in dialysis patients. However, iron may harbour detrimental effects in being a nutrient for invading pathogens or by modulating immune pathways. Thus, we prospectively studied the effects of iron treatment towards monocyte immune function. METHODS: Twenty-four haemodialysis patients in whom iron therapy was withheld for 2 weeks before study entry were randomly assigned to receive either a single parenteral dose of iron sucrose or saline (control), and the effects on iron status and immune function of patients' monocytes were analysed during follow-up. RESULTS: At baseline, we found an inverse relationship between serum ferritin levels and the inducibility of patients' monocytes for interleukin-6 and tumour necrosis factor-alpha formation following ex vivo immune stimulation. However, 48 h after intravenous iron administration, we observed a transient increase of tumour necrosis factor-alpha and interleukin-6 formation by unstimulated monocytes as compared with control subjects. This could be traced back to increased phosphorylation of nuclear factor kappa-B p65 in monocytes following iron treatment, which was more pronounced when pre-treatment serum ferritin levels were low. In parallel, intravenous iron injection resulted in storage of the metal in circulating monocytes as reflected by an increase of intracellular ferritin levels, and the amount of iron retention was positively associated with circulating concentrations of the iron regulatory peptide hepcidin. CONCLUSIONS: Intravenously administered iron is taken up by monocytes and leads to short-term activation of the nuclear factor kappa-B pathway. However, increased circulating ferritin levels are associated with an impaired immune response of monocytes. In addition, circulating hepcidin concentrations may determine the erythropoietic response to iron injection by modifying iron retention within monocytes.
Authors: Irene Cortés-Puch; Dong Wang; Junfeng Sun; Steven B Solomon; Kenneth E Remy; Melinda Fernandez; Jing Feng; Tamir Kanias; Landon Bellavia; Derek Sinchar; Andreas Perlegas; Michael A Solomon; Walter E Kelley; Mark A Popovsky; Mark T Gladwin; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson Journal: Blood Date: 2013-12-23 Impact factor: 22.113
Authors: Vaijinath S Kamanna; Shobha H Ganji; Stanislav Shelkovnikov; Keith Norris; Nosratola D Vaziri Journal: Am J Nephrol Date: 2011-12-29 Impact factor: 3.754
Authors: Céline Vaugier; Mariane T Amano; Jonathan M Chemouny; Michael Dussiot; Claire Berrou; Marie Matignon; Sanae Ben Mkaddem; Pamella H M Wang; Aurélie Fricot; Thiago T Maciel; Damien Grapton; Jacques R R Mathieu; Carole Beaumont; Marie-Noëlle Peraldi; Carole Peyssonnaux; Laurent Mesnard; Eric Daugas; François Vrtovsnik; Renato C Monteiro; Olivier Hermine; Yelena Z Ginzburg; Marc Benhamou; Niels O S Camara; Martin Flamant; Ivan C Moura Journal: J Am Soc Nephrol Date: 2017-08-07 Impact factor: 10.121
Authors: Ingrid Hougen; David Collister; Mathieu Bourrier; Thomas Ferguson; Laura Hochheim; Paul Komenda; Claudio Rigatto; Navdeep Tangri Journal: Clin J Am Soc Nephrol Date: 2018-02-20 Impact factor: 8.237
Authors: Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart Journal: Am J Med Date: 2013-04-15 Impact factor: 4.965
Authors: Gianluigi Zaza; Simona Granata; Federica Rascio; Paola Pontrelli; Maria Pia Dell'Oglio; Sharon Natasha Cox; Giovanni Pertosa; Giuseppe Grandaliano; Antonio Lupo Journal: BMC Med Genomics Date: 2013-05-10 Impact factor: 3.063